TP53 and vaginal cancer: Management of vaginal cancer requires an individualized approach, considering patient preferences, the disease stage, and prognostic factors, including HPV status [45], p16 expression, p53 mutation status [46,47], tumor size, FIGO stage, lymph node involvement, and response to primary treatment [51].